These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28011623)

  • 21. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
    Beuselinck B; Job S; Becht E; Karadimou A; Verkarre V; Couchy G; Giraldo N; Rioux-Leclercq N; Molinié V; Sibony M; Elaidi R; Teghom C; Patard JJ; Méjean A; Fridman WH; Sautès-Fridman C; de Reyniès A; Oudard S; Zucman-Rossi J
    Clin Cancer Res; 2015 Mar; 21(6):1329-39. PubMed ID: 25583177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
    Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N
    J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.
    de Boüard S; Herlin P; Christensen JG; Lemoisson E; Gauduchon P; Raymond E; Guillamo JS
    Neuro Oncol; 2007 Oct; 9(4):412-23. PubMed ID: 17622648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
    Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P
    Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sunitinib treatment reduces tumor growth and limits changes in microvascular properties after minor surgical intervention in an in vivo model of secondary breast cancer growth in bone.
    Schroeder M; Viezens L; Wellbrock J; Fiedler W; Rüther W; Algenstaedt P; Hansen-Algenstaedt N; Schaefer C
    J Surg Oncol; 2016 Apr; 113(5):515-21. PubMed ID: 26818116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sunitinib paves the way for targeted therapies in neuroendocrine tumors.
    Raymond E; Faivre S; Hammel P; Ruszniewski P
    Target Oncol; 2009 Dec; 4(4):253-4. PubMed ID: 19911111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
    Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
    J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
    Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
    PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.
    Prior C; Perez-Gracia JL; Garcia-Donas J; Rodriguez-Antona C; Guruceaga E; Esteban E; Suarez C; Castellano D; del Alba AG; Lozano MD; Carles J; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Gurpide A; Lopez-Picazo JM; Hernandez AG; Mellado B; Martínez E; Moreno F; Font A; Calvo A
    PLoS One; 2014; 9(1):e86263. PubMed ID: 24475095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis.
    Gandhi L; McNamara KL; Li D; Borgman CL; McDermott U; Brandstetter KA; Padera RF; Chirieac LR; Settleman JE; Wong KK
    Cancer Prev Res (Phila); 2009 Apr; 2(4):330-7. PubMed ID: 19336729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia.
    Matsumoto S; Batra S; Saito K; Yasui H; Choudhuri R; Gadisetti C; Subramanian S; Devasahayam N; Munasinghe JP; Mitchell JB; Krishna MC
    Cancer Res; 2011 Oct; 71(20):6350-9. PubMed ID: 21878530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of sunitinib in extraskeletal myxoid chondrosarcoma.
    Stacchiotti S; Pantaleo MA; Astolfi A; Dagrada GP; Negri T; Dei Tos AP; Indio V; Morosi C; Gronchi A; Colombo C; Conca E; Toffolatti L; Tazzari M; Crippa F; Maestro R; Pilotti S; Casali PG
    Eur J Cancer; 2014 Jun; 50(9):1657-64. PubMed ID: 24703573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined effect of vascular-leakage-blocker Sac-1004 and antiangiogenic drug sunitinib on tumor angiogenesis.
    Lee K; Agrawal V; Kim K; Kim J; Park H; Lee S; Kim YM; Suh YG; Kwon YG
    Biochem Biophys Res Commun; 2014 Aug; 450(4):1320-6. PubMed ID: 25003323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.
    Chahal M; Xu Y; Lesniak D; Graham K; Famulski K; Christensen JG; Aghi M; Jacques A; Murray D; Sabri S; Abdulkarim B
    Neuro Oncol; 2010 Aug; 12(8):822-33. PubMed ID: 20179017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small molecule.
    Argyros O; Karampelas T; Varela A; Asvos X; Papakyriakou A; Agalou A; Beis D; Davos CH; Fokas D; Tamvakopoulos C
    Oncotarget; 2017 Jun; 8(23):37250-37262. PubMed ID: 28422745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.
    Shojaei F; Lee JH; Simmons BH; Wong A; Esparza CO; Plumlee PA; Feng J; Stewart AE; Hu-Lowe DD; Christensen JG
    Cancer Res; 2010 Dec; 70(24):10090-100. PubMed ID: 20952508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sunitinib: from rational design to clinical efficacy.
    Chow LQ; Eckhardt SG
    J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.
    Garcia-Donas J; Leandro-García LJ; González Del Alba A; Morente M; Alemany I; Esteban E; Arranz JA; Climent MA; Gallardo E; Castellano DE; Bellmunt J; Mellado B; Puente J; Moreno F; Font A; Hernando S; Robledo M; Rodríguez-Antona C
    Ann Oncol; 2013 Sep; 24(9):2409-14. PubMed ID: 23788753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does Hypoxic Response Mediate Primary Resistance to Sunitinib in Untreated Locally Advanced Breast Cancer?
    Braga S; Cardoso J; Andre S; Brito M; Sanchez P; Orvalho L; Salgado L; Dias S; Pereira-Leal JB; Passos-Coelho JL
    Curr Cancer Drug Targets; 2017; 17(1):62-73. PubMed ID: 27784207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiangiogenic therapy for breast cancer.
    Nielsen DL; Andersson M; Andersen JL; Kamby C
    Breast Cancer Res; 2010; 12(5):209. PubMed ID: 21067536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.